• No results found

A study of the clinical picture, visual prognosis and treatment outcome of uveitis in Behçet’s disease

N/A
N/A
Protected

Academic year: 2019

Share "A study of the clinical picture, visual prognosis and treatment outcome of uveitis in Behçet’s disease"

Copied!
8
0
0

Loading.... (view fulltext now)

Full text

(1)

S.NO AGE SEX ST U DY EYE COMPLAINTS DEFECTIVE VISION PAIN WATERING

PHOTOPHOBIA REDNESS FLOATERS

OC

U

LAR FINDINGS LATERALITY

VIS U AL AC U ITY AT PRESENTATION VIS U AL AC U

ITY AT FINAL VISIT

PATHOLOGY SEVERITY CHRONICITY AGE AT ONSET

ACT

U

AL D

U

RATION OF

SYMPTOMS (DAYS) AT FIRST

PRESENTATION LOCATION INTRAOC U LAR PRESS U RE

ANTERIOR SEGMENT MANIFESTATIONS

SCLERITIS CONJ U NCTIVAL U LCER KERATITIS KERATIC PRECIPITATES

HYPOPYON CELLS FLARE IRIS NOD

U LES LENS STAT US EXTRAOC U LAR M U SCLE INVOLVEMENT

POSTERIOR SEGMENT MANIFESTATIONS

MEDIA

VITREO

U

S CELLS

SNOW BANK SNOW BALLS RETINITIS VASC

U LITIS VITREO U S OPACITIES/MEMBRRANE NEOVASC U LARISATION

OPTIC NERVE EDEMA MAC

U

LAR EDEMA OTHERS

EXTRAOC U LAR MANIFESTATIONS RECC U RENT ORAL U LCERS GENITAL U LCERS

ARTHRITIS SKIN LESIONS THRMBOPHLEBITIS CNS INVOLVEMENT

OTHERS

PAST TREATMENT O

U TSIDE MEDICATION IF IMM U NOS U PRESSIVE SU RGICAL OTHERS FL U

ORESCEIN ANGIOGRAPHY OPTICAL COHERENCE

TOMOGRAPHY PATHERGY TEST

U

LTRASONOGRAPHY

OTHERS

COMMENTS TREATMENT TOPICAL STEROID ORAL STEROID

POSTERIOR S

U

BTENON

INJECTION STEROID IMM

U

NOS

U

PPRESSIVE

1 23 M 1 1 0 0 0 1 1 3 2/60 2/60 2 3 2 22 365 4 11 0 0 0 0 0 1 1 0 2 0 1 1 0 0 0 1 1 0 0 1 0 1 1 0 0 0 0 0 2 3 1 0 0

FOVEAL ATROPHY, LOSS OF FOVEAL THICKNESS

0 1 0 1

2 0 0 0 0 0 1 3 6/6 6/12 2 1 2 22 365 3 13 0 0 0 0 0 0 0 0 2 0 1 1 0 0 0 1 1 0 0 0 0 1 1 0 0 0 0 0 2 3 1 0 0 0 1 0 1

2 49 M 2 1 1 0 0 1 0 2 6/24 6/24 2 2 2 49 10 1 20 0 0 0 1 0 1 1 0 3 0 1 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 2 3 1 0 0 1 0 0 0

3 19 M 1 1 0 0 0 0 0 3 6/24 6/18 2 2 2 17 730 4 32 0 0 0 0 0 1 1 0 2 0 2 0 0 0 0 1 0 0 0 1 0 1 0 0 0 0 0 0 1 1 0 0 0 1 1 0 1

2 1 0 0 0 0 0 3 6/36 6/36 2 2 2 17 730 4 30 0 0 0 0 0 1 1 0 2 0 2 0 0 0 0 1 0 0 0 1 0 1 0 0 0 0 0 0 1 1 0 0 0 1 1 0 1

4 29 M 1 1 0 0 0 0 0 3 PL-VE PL-VE 2 3 1 29 183 4 56 0 0 0 0 0 0 1 0 1 0 2 1 0 0 0 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0

2 1 0 0 0 0 0 3 1/2 / 60 1/2 / 60 2 3 1 29 183 4 10 0 0 0 0 0 0 0 0 1 0 1 1 0 0 0 1 1 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0VITREOUS HAEMORRHAGE

HYPER REFLECTIVE LESION AT MACULA, FOVEAL

0 1 0 0

5 13 M 1 1 0 0 1 0 1 3 3/60 6/12 2 3 2 13 7 4 11 0 0 0 1 0 1 1 0 1 0 1 1 0 1 1 1 1 0 0 1 0 1 1 0 1 0 0 0 0 0 0 0 0

TOTAL LOSS OF VESSELS, CNPs, FOVEA NOT MADE OUT

1 1 0 1

2 1 0 0 1 0 1 3 3/60 6/6 2 3 2 13 7 4 18 0 0 0 1 0 1 1 0 1 0 1 1 0 1 1 1 1 0 0 0 0 1 1 0 1 0 0 0 0 0 0 0 0 1 1 0 1

6 22 M 1 1 0 0 0 1 0 3 6/6 6/6 2 2 2 21 365 4 26 0 0 0 1 0 1 1 0 1 0 1 1 0 0 0 0 1 0 0 0 0 1 0 0 1 0 0 0 1 1 0 0 0 1 1 0 0

2 1 0 0 0 1 0 3 6/6 6/6 2 2 2 21 365 4 39 0 0 0 1 0 1 1 0 1 0 1 1 0 0 0 0 1 0 0 0 0 1 0 0 1 0 0 0 1 1 0 0 0 1 1 0 0

7 24 M 1 1 1 0 0 1 0 3 6/6 HM+ 2 1 2 21 1095 4 6 0 0 0 1 0 1 1 0 1 0 1 1 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 1 3 6 0 0 NORMAL THIN ERM 0 1 1 1

2 1 0 0 0 0 0 3 6/6 6/60 2 3 2 21 1095 4 6 0 0 0 1 0 1 1 0 1 0 1 1 0 0 1 1 1 0 0 0 0 1 1 0 0 0 0 0 1 3 6 0 0

EARLY BLOCKED FLUORESCENE WITH LATE STAINING OF SUBRETINAL THIN ERM. FOVEAL ATROPHY

(2)

8 24 M 1 0 0 0 0 0 0 3 6/6 6/6 2 2 2 24 10 4 6 0 0 0 1 0 1 1 0 1 0 1 1 0 0 0 1 1 0 0 1 0 1 1 0 0 0 0 0 1 1 0 0 0 1 1 1 1

2 1 1 0 0 1 0 3 HM+ 6/60 2 3 2 24 10 4 6 0 0 0 1 0 1 1 0 1 0 1 1 0 0 0 1 1 0 0 1 0 1 1 0 0 0 0 0 1 1 0 0 0 1 1 1 1

9 35 M 2 1 1 1 1 1 1 2 6/9 6/24 2 3 1 35 10 4 10 0 0 0 1 1 1 1 0 4 0 1 1 0 0 0 1 0 0 0 1 0 1 1 1 0 0 0 0 1 1 0 0 0

SEROUS DETACHMENT AT THE MACULA

1 1 1 0

10 38 M 1 1 0 0 0 0 1 3 6/24 6/18 2 2 2 33 1825 4 12 0 0 0 1 0 1 1 0 1 0 1 1 0 0 0 1 0 0 0 1 0 1 1 0 1 0 0 0 1 1 0 0 0 1 1 1 1

2 1 0 0 0 0 1 3 6/6 6/12 2 2 2 33 1825 4 13 0 0 0 1 0 0 0 0 1 0 1 1 0 0 0 1 0 0 0 1 0 1 1 0 1 0 0 0 1 1 0 0 0 1 1 1 1

11 34 M 1 1 1 0 0 1 0 1 6/60 5/60 2 2 2 34 180 4 16 0 0 0 1 1 1 1 0 1 0 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 2 1 0 0 0 MILD MACULAR EDEMA 1 1 1 0

12 30 M 1 1 0 0 0 0 0 3 1/2 / 60 1/2 / 60 2 3 2 27 1095 4 24 0 0 0 1 1 1 1 0 2 0 2 1 0 0 0 0 1 0 0 0 0 1 0 1 0 0 0 0 2 3 4 0 0

?VASCUL ITIS WITH VH

1 1 0 1

2 0 0 0 0 0 0 3 6/24 6/18 2 1 2 27 1095 4 15 0 0 0 0 0 1 1 0 3 0 2 1 0 0 0 0 1 0 0 0 0 1 0 1 0 0 0 0 2 3 4 0 0 0 1 0 1

13 31 M 2 1 1 0 0 1 0 2 6/6 6/6 2 1 2 30 240 2 11 0 0 0 0 0 0 0 0 1 0 1 1 0 0 0 0 0 0 0 0 0 1 1 1 0 0 1 0 2 3 1,7 0 0

RE .LSS OF FOVEAL THICKNESS AND CONTOUR, POST CSR

0 1 0 1

14 33 F 1 0 1 0 0 1 0 3 6/6 6/6 2 2 2 33 30 4 18 0 0 0 1 0 1 1 0 1 0 1 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 1 0 0 0

POSTERI OR SCLERITIS

1 1 0 1

2 0 1 0 0 1 0 3 6/6 6/6 2 2 2 33 30 4 20 1 0 0 1 0 1 1 0 1 0 1 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 1 0 0 0 1 1 0 1

15 44 M 1 0 0 0 0 0 0 3 6/6 6/6 2 1 2 44 7 4 35 0 0 0 0 0 1 1 0 1 0 1 1 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0

2 1 0 0 0 0 0 3 4/60 6/6 2 3 2 44 7 4 42 0 0 0 1 0 1 1 0 1 0 1 1 0 0 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0

16 34 M 1 1 0 0 0 0 1 3 6/18 6/6 2 2 2 33 365 4 10 0 0 0 0 0 0 0 0 1 0 1 1 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 0 2 1 0 0 0 1 1 0 0

(3)

17 31 M 1 1 0 0 0 0 1 3 6/6 6/6 2 2 2 31 547 4 17 0 0 0 1 0 1 1 0 1 0 1 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 2 3 5 0 0 1 1 0 1

2 1 0 0 0 0 1 3 6/6 6/6 2 2 2 31 547 4 20 0 0 0 0 0 1 1 0 1 0 1 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 2 3 5 0 0 1 1 0 1

18 28 M 1 1 1 0 0 1 0 3 6/18 6/18 2 2 2 28 365 4 20 0 0 0 1 0 0 0 0 1 0 1 1 0 0 0 1 1 0 0 0 0 1 0 1 0 0 0 0 2 3 1 0 0 1 1 1 1

2 1 1 0 0 1 0 3 6/9 6/9 2 2 2 28 365 4 19 0 0 0 1 0 0 0 0 1 0 1 1 0 0 0 1 0 0 0 0 0 1 0 1 0 0 0 0 2 3 1 0 0 1 1 1 1

19 44 M 1 1 0 0 1 0 0 3 6/9 6/9 2 1 2 44 60 4 11 0 0 0 0 0 1 1 0 1 0 1 0 0 0 0 0 1 0 0 1 0 1 0 1 0 0 0 0 2 3 4,6 0METFORMIN TAB 0 0 0 0

2 0 0 0 0 0 0 3 6/6 6/6 2 1 2 44 60 4 13 0 0 0 0 0 1 1 0 1 0 1 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 2 3 0 0METFORMIN TAB 0 0 0 0

20 40 M 1 1 0 0 0 0 0 3 HM+ FCF 2 3 2 36 1460 4 14 0 0 0 0 0 1 1 0 2 0 2 1 0 0 0 1 0 0 0 0 0 1 1 0 0 0 0 0 2 3 5 0 0 1 1 0 1

2 1 0 0 0 0 0 3 6/18 6/6 2 3 2 36 1460 4 14 0 0 0 0 0 1 1 0 3 0 2 1 0 0 0 1 0 0 0 0 0 1 1 0 0 0 0 0 2 3 5 0 0 CNP AREAS 1 1 0 1

21 25 M 1 1 0 0 0 0 0 3 PL+VE 1/60 2 3 2 20 1825 4 8 0 0 0 1 0 1 1 0 2 0 2 1 0 0 0 1 0 0 0 0 0 1 1 1 0 0 0 0 1 3 4,5 0 0 0 1 0 1

2 1 0 0 0 0 0 3 1/60 1/60 2 3 2 20 1825 4 7 0 0 0 1 0 1 1 0 3 0 1 1 0 0 0 1 0 0 0 0 0 1 1 1 0 0 0 0 1 3 4,5 0 0 0 1 0 1

22 26 M 1 1 0 0 0 0 0 3 1/60 1/60 2 3 2 20 2190 4 17 0 0 0 1 0 1 1 0 1 0 1 1 0 0 1 1 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0ACTIVE VASCULITIS 0 1 0 1

2 1 0 0 0 0 0 3 6/6 6/6 2 3 2 20 2190 4 18 0 0 0 0 0 0 0 0 1 0 1 1 0 0 1 1 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0ACTIVE VASCULITIS 0 1 0 1

23 33 M 1 1 0 0 0 1 0 3 5/60 6/24 2 3 2 33 25 4 17 0 0 0 1 0 1 1 0 3 0 1 1 0 0 0 1 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1

2 1 0 0 0 0 0 3 1/60 6/36 2 3 2 33 25 4 24 0 0 0 1 1 1 1 0 3 0 1 1 0 0 0 1 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1

(4)

2 1 0 0 0 0 0 3 6/60 6/9 2 3 2 16 3650 4 9 0 0 0 1 1 1 1 0 2 0 2 1 0 0 0 1 1 0 1 1 0 1 1 0 0 0 0 0 0 0 0 0 0 CME 1 1 1 0

25 18 M 1 1 0 0 0 0 0 3 1/60 FCF 2 3 2 15 1095 4 30 0 0 0 1 0 1 1 0 2 0 2 1 0 0 0 1 1 0 0 1 0 1 1 0 0 0 0 0 2 3 5 0 0 1 1 1 1

2 1 0 0 0 0 0 3 PL-VE PL-VE 2 3 2 15 1095 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0

26 14 M 1 1 0 1 1 1 1 3 3/60 6/9 2 3 2 14 365 4 32 0 0 0 1 1 1 1 0 1 0 1 1 1 1 1 1 1 0 1 1 0 0 0 1 0 0 0 0 1 1 0 0 0 1 1 0 1

2 1 0 1 1 1 1 3 6/9 6/9 2 3 2 14 365 4 34 0 0 0 1 0 1 1 0 1 0 1 1 1 1 1 1 1 0 1 1 0 0 0 1 0 0 0 0 1 1 0 0 0 1 1 0 1

27 22 M 1 0 0 0 0 0 0 3 6/6 6/6 2 3 2 22 730 4 18 0 0 0 1 0 1 1 0 1 0 1 1 1 1 0 1 0 0 1 0 0 1 1 1 0 0 0 0 1 1 0 0 0 1 1 1 1

2 1 0 0 1 0 0 3 6/6 6/18 2 3 2 22 730 4 16 0 0 0 1 0 1 1 0 1 0 1 1 1 1 1 1 0 0 1 0 0 1 1 1 0 0 0 0 1 1 0 0 0 1 1 1 1

28 19 F 1 0 0 0 0 0 1 3 6/6 PL+VE 2 3 2 19 90 4 14 0 0 0 1 1 1 1 1 1 0 2 1 1 1 1 1 1 0 1 1 0 1 1 0 0 0 0 0 1 3 6 0 0 1 1 1 1

2 0 0 0 1 1 0 3 6/6 5/60 2 3 2 19 90 4 12 0 0 0 1 1 1 1 0 1 0 2 1 0 0 1 1 1 0 1 1 0 1 1 0 0 0 0 0 1 3 6 0 0 1 1 1 1

29 23 M 1 1 1 0 0 1 0 3 PL-VE N/A 2 3 2 21 730 4 N/A 0 0 0 0 0 1 1 0 1 0 2 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 3 1,2 0 0 0 1 0 1

2 1 1 0 0 0 0 3 4/60 1/2 / 60 2 3 2 21 730 4 13 0 0 0 1 1 1 1 0 2 0 2 1 0 1 1 0 0 0 0 0 0 1 0 0 0 0 0 0 1 3 1,2 0 0 1 1 1 1

(5)

IMM

U

N

U

PRESSIVE(SPECIFIC) SURGICAL OTHERS

COMPLICATIONS SYNECHIAE

RU

BEOSIS

CATARACT

VITREO

U

S HAEMORRHAGE GLAU

COMA

OPTIC ATROPHY

NEOVASC

U

LARISATION

MAC

U

LAR EDEMA

MAC

U

LAR DEGENERATION MAC

U

LAR HOLE

EPIRETINAL MEMBRANE VENO

U

S OCCL

U

SION

RETINAL TEAR

RETINAL DETACHMENT

PTHISIS B

U

LBI

END STAGE DISEASE

OTHERS

1 0 0 0 0 1 0 0 1 0 1 1 0 1 0 0 0 0 0 0

1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

5 PRP,AADI 0 0 0 1 0 4 0 0 1 0 0 0 0 0 0 0 0 0

5 PRP,AADI 0 0 0 1 0 4 0 0 1 0 0 0 0 0 0 0 0 0

0 0 0 1,2 1 0 1 3 0 0 0 0 0 0 0 0 0 0 1 0

0 PRP 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0

1,6 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0

1,6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0

0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0

6 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0

(6)

1,6 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0

1,6 0 0 2 0 0 0 0 0 0 1 1 0 1 0 0 0 0 0 0

0

VITREOUS TAP, INTRAVITREAL V + C + D, CORE VITRECTOMY

0 0 0 0 0 0 0 0 1 0 0 1 0 0 1 0 0 0

1 0 0 0 0 0 0 2 0 0 1 0 0 1 0 0 0 0 0 0

1 0 0 0 0 0 0 2 0 0 1 0 0 1 0 0 0 0 0 0

0 0 0 2 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0

4 0 0 2 0 1 0 4 0 0 0 0 0 0 0 0 0 0 0 0

4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

1,7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0CSR OTHER EYE

1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 0

BRIMONIDINE FOR GLACUOMA

0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0

0 0

BRIMONIDINE FOR GLACUOMA

0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0

0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

(7)

7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0ALLERGY TO CICLOSPORINE

7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0ALLERGY TO CICLOSPORINE

1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0

1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0

0 0

CAP MACUGOLD(V ITAMIN A)

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CSR

0 0

CAP MACUGODL(V ITAMIN A)

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

1 PHACO 0 0 0 1 0 0 1 0 0 1 0 1 0 0 0 0 1 0

1 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0

1 SICS 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0

1 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 1 0

1 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0

1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

1 0GLUCOMOL FOR IOP RISE 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0

1 0GLUCOMOL FOR IOP RISE 2 0 0 1 0 0 0 0 1 0 1 0 0 0 0 0 0

(8)

4 0 0 2 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0

1, 4 TRAB,PHACO COMBIGAN, DORZOX T 2 0 1 0 4 0 0 1 0 0 1 0 0 0 0 0 0

0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0

1,4 0 0 2 0 0 0 2 0 0 1 0 0 1 0 0 1 0 0 0

0 0 0 0 2 0 0 1 0 0 1 0 0 0 0 0 0

1 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

1,2,6,7 0 0 2 0 1 0 0 1 0 1 0 0 1 0 0 0 0 1 0

0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0

1,2 ENUCLEATION 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0

1,2 PHACO 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0

References

Related documents

This proposed configuration is referred to as Circular Ring Patch with Inner and External Resonator and Extended Feeder by 10.0 mm (CRPIER EF 10.0) antenna and it is shown in

Overview of experimental results for the average total γ -ray energy released in fission (upper part), the average energy per photon (middle part) and prompt fission γ -ray

Da alle viralen Gene, die in EBV- immortalisierten B-Zellen exprimiert werden, CSL-Bindungsstellen im Promotor aufweisen, kann man jedoch vermuten, dass diese sowohl durch EBNA2

We calculate the correlators of vector and axial currents in external strong abelian magnetic field in SU(3) gluodynamics.From the correlators the masses (ground state energies)

The present study was conducted to examine the growth and variability in area, production and yield of wheat crop in all provinces (i.e. Khyber Pakhtunkhwa,

The results of the head teachers’ responses revealed that the performance of their District Educational Administrators was average and for the performance

The main objective of the study was to locate iron ore mineral deposits of Mbeu area by conducting ground magnetic survey based on magnetic properties of subsurface rocks

Our results show that the rats via IP injection at a dose of mercury from 0.25 mg / kg, causes a diminition in phagocytic activity after 48 hours of injection and